Immune Modulation and Cytomegalovirus Reactivation in Sepsis-induced Immunosuppression: A Pilot Study

Area of Science:

• Critical Care Medicine
• Immunology
• Infectious Diseases

Background:

• Sepsis involves immune dysregulation and immunosuppression, increasing risks.
• Cytomegalovirus (CMV) reactivation frequently occurs in sepsis patients, correlating with adverse outcomes.
• Understanding the link between sepsis-induced immunosuppression and CMV reactivation is crucial for managing prolonged sepsis.

Purpose of the Study:

• To investigate the association between cytomegalovirus (CMV) reactivation and immune alterations in patients with sepsis-induced immunosuppression.
• To identify immune markers indicative of CMV reactivation in patients with prolonged sepsis.

Main Methods:

• Prospective enrollment of severe sepsis patients (CMV IgG positive) in the ICU, excluding other immunosuppression causes.
• Weekly sample collection for CMV viral load quantification (qPCR) and immune marker analysis via flow cytometry.
• Analysis included lymphocyte subsets, HLA-DR on monocytes, PD-1 on T cells, and cytokine levels (IL-6, TNF-α, IFN-γ, IL-2, IL-4, IL-10).

Main Results:

• CMV reactivation occurred in 20 of 25 patients, who exhibited T-cell lymphopenia.
• Elevated PD-1 expression on T cells (CD4+, CD8+) and significantly low HLA-DR on monocytes were observed in CMV-reactivated patients.
• Increased IL-6 and IL-10 levels were noted in the CMV-reactivated group compared to non-reactivated patients.

Conclusions:

• Immune suppression markers and altered cytokine profiles are significantly associated with CMV reactivation in severe sepsis.
• These findings highlight the interplay between sepsis-induced immunosuppression and viral reactivation.
• Further research can explore targeted immunomodulatory therapies for sepsis patients with CMV reactivation.